Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery

Panyam, J. & Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329–347 (2003).

Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech. 2, 751–760 (2007).

Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature Rev. Drug Discov. 9, 615–627 (2010).

Choi, H. S. et al. Design consideration for tumour-targeted nanoparticles. Nature Nanotech. 5, 42–47 (2010).

Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T. & Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nature Biotechnol. 23, 1418–1423 (2005).

De Jong, W. H. & Borm P. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 3, 133–149 (2008).

Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).

Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).

Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D. W. Y. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chem. Biol. 2, 711–719 (2006).

Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nature Rev. Drug Discov. 8, 129–138 (2009).

Oh, Y. K. & Park, T. G. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61, 850–862 (2009).

Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Rel. 114, 100–109 (2006).

Bhatia, D. et al. A synthetic icosahedral DNA-based host–cargo complex for functional in vivo imaging. Nature Commun. 2, 339 (2011).

Walsh, A. S., Yin, H., Erben, C. M., Wood, M. J. A. & Tuberfield, A. J. DNA cage delivery to mammalian cells. ACS Nano 5, 5427–5432 (2011).

Keum, J. W., Ahn, J. H. & Bermudez, H. Design, assembly, and activity of antisense DNA nanostructures. Small 7, 3529–3535 (2011).

Gaglione, M. & Messere, A. Recent progress in chemically modified siRNAs. Mini Rev. Med. Chem. 10, 578–595 (2010).

Davis, M. E., Chen, Z. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev. Drug Discov. 7, 771–782 (2008).

Allen, T. M. & Cullis, P. R. Drug delivery systems: entering the mainstream. Science 303, 1818–1822 (2004).

Mok, H., Lee, S. H., Park, J. W. & Park, T. G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nature Mater. 9, 272–278 (2010).

Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol. 23, 709–717 (2005).

Li, S. D., Chen, Y. C., Hackett, M. J. & Huang, L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 16, 163–169 (2008).

Tarapore, P., Shu, Y., Guo, P. & Ho, S. M. Application of Phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and surviving in ovarian cancers. Mol. Ther. 19, 386–394 (2011).

Manz, B. N. et al. T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters. Proc. Natl Acad. Sci. USA 108, 9089–9094 (2011).

Nahrendorf, M. et al. Hybrid PET-optical imaging using targeted probes. Proc. Natl Acad. Sci. USA 107, 7910–7915 (2010).

Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nature Biotechnol. 29, 1005–1010 (2011).

Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).